Home » Advocacy » Letters, Testimony & Comments

Letters, Testimony & Comments

BIO Letter to Ontario Premier on Gene Patenting
September 26, 2001
The Honorable Michael Harris, M.P.P. Premier of Ontario Legislative Assembly of Ontario Room 281 Legislative Building Toronto, Ontario M7A 1A1 Dear Premier Harris: I read with concern your remarks about modifying Canadian patent laws to...
BIO letter to Rep. Michael Bilirakis, Chairman, Energy & Commerce Cmte., Subcommittee on Health
July 26, 2001
Honorable Michael Bilirakis Chairman Subcommittee on Health Committee on Energy and Commerce U.S. House of Representatives 2125 Rayburn Building Washington, DC 20015 Dear Mr. Chairman: On June 13, your Subcommittee held a hearing...
Building biotech in Ohio, You can if you think you can
July 13, 2001
Dan Eramian, Vice President Communications Biotechnology Industry Organization Athersys Cleveland, Ohio July 13, 2001 Let me start by telling you a little about the Biotechnology Industry Organization, or BIO. We are the national...
Statement of J. Craig Venter, PhD, President, Celera Genomics
July 11, 2001
Written Statement of J. Craig Venter, PhD, President, Celera Genomics On Behalf of The Biotechnology Industry Organization (BIO) Before the Subcommittee on Consumer Protection US House Committee on Energy and Commerce July 11, 2001 Good...
House Energy and Commerce Committee Testimony
June 20, 2001
Good afternoon. My name is Thomas Okarma. I am the President and CEO of Geron Corporation in Menlo Park, California. Geron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic and diagnostic products for...
Testimony of Thomas Okarma, PhD, MD President and CEO of Geron Corporation On Behalf of Biotechnology Industry Organization (BIO) Before the Subcommittee on Crime, House Judiciary Committee
June 19, 2001
Good afternoon. My name is Thomas Okarma. I am the President and CEO of Geron Corporation in Menlo Park, California. Geron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic and diagnostic products...
Prescription Drug Benefits as Part of Medicare Modernization
May 10, 2001
Executive Summary The Biotechnology Industry Organization (BIO) supports amendment of the current reexamination authority to enhance patent quality. Congress established the patent reexamination system in 1980 as an ex parte proceeding that could be...
Letter to Mr. Nicholas Godici
May 4, 2001
Acting Undersecretary of Commerce and Acting Director of the United States Patent and Trademark Office Regarding Patent Law Harmonization
Testimony of Carl B. Feldbaum Before the Senate Commerce Committee Subcommittee on Science, Technology and Space
May 2, 2001
Good afternoon. My name is Carl Feldbaum. I am the president of the Biotechnology Industry Organization, otherwise known as BIO. BIO represents more than 950 biotechnology companies, academic institutions and state biotechnology centers in all 50 U....
PTO response to Carl Feldbaum on International Patent Harmonization Efforts
May 1, 2001
Disclosure of Information
April 18, 2001
The Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and...
BIO comments on FDA proposed rule regarding disclosure of certain information in gene therapy and xenotransplantation experiments
April 18, 2001
The Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and...
Anything Under the Sun Made by Man
April 11, 2001
By: Lila Feisee BIO's Director for Federal Government Relations and Intellectual Property Consider this: We all know that Alexander Fleming discovered penicillin. Some of us know he did it in 1928. But how many people can tell you who...
TESTIMONY OF THOMAS OKARMA, MD, PhD PRESIDENT AND CEO OF GERON CORPORATION ON BEHALF OF THE BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) BEFORE THE SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS COMMITTEE ON ENERGY AND COMMERCE US HOUSE OF REPRESENTATIV
March 30, 2001
Summary of Testimony of Thomas Okarma, MD, PhD BIO opposes human reproductive cloning. It is too dangerous technically and raises too many ethical and social questions. The voluntary moratorium on human reproductive cloning should remain in...
Letter to President George Bush Regarding Cloning
February 1, 2001
Dear Mr. President: Recently certain groups have announced plans to clone human beings. The Biotechnology Industry Organization (BIO) opposes these efforts, and we urge you to support continuation of the current voluntary moratorium on these...
Stop, Look and Listen
February 1, 2001
By Dan Eramian Vice President Communications Biotechnology Industry Organization Delivered at the Global Public Affairs Institute Johnson & Johnson New Brunswick, New Jersey February 1, 2001 Good Morning … thank you for...
BIO Position on Stem Cell Research
January 17, 2001
President-Elect George W. Bush Bush-Cheney Transition Headquarters 1800 G Street, N.W. Washington, DC 20270 Dear President-Elect Bush: The undersigned 123 patient, research, and academic institutions, write to express their strong support...
Recombinant DNA Research
December 12, 2000
The Biotechnology Industry Organization (BIO) submits these comments on the proposal published by the National Institutes of Health (NIH) in 65 Fed. Reg. 77655 (December 12, 2000), to revise the "NIH Guidelines for Research Involving...
BIO Members Testify before House Judiciary Subcommittee
July 13, 2000
WASHINGTON, D.C. (July 13, 2000) -- Executives from two Biotechnology Industry Organization (BIO) member companies testified today at a U.S. House Judiciary subcommittee oversight hearing on gene patents and other genomic inventions. In his...
BIO 2000 Opening Plenary Speech / Boston
June 1, 2000
By Carl B. Feldbaum, President Ladies and Gentlemen, I'm Carl Feldbaum, President of the Biotechnology Industry Organization, otherwise known as BIO. I want to welcome you here to Boston, and to BIO 2000, which is by far our largest, and...